Investing in tangible medical improvement
InvHealth Capital Inc. (InvHealth) invests in business opportunities exclusively in the field of healthcare. InvHealth is focused on medical solutions that have the potential to provide tangible improvement over standard of care and with a favourable socio-economic balance. With constant rising healthcare costs, good science and clinical data alone are not enough. A successful and financially rewarding medical solution also has to be practical and affordable for the patients / payers.
InvHealth leverages its unique set of expertise and extensive network of universities, institutions and pharmaceutical companies developed over the past 35 years. Whether it is to perform comprehensive due diligence prior to an investment or commercial transaction (e.g. licensing, collaboration, M&A) or to develop a strategic plan for any given product opportunity, InvHealth’s team can provide advice as required:
Chemistry & manufacturing
Small molecules, Peptides / Proteins
Pre-Clinical – Translational medecine
Exploratory in Vivo / in Vitro Study
IND Enabling Pharmacology
Clinical & Regulatory
Corporate Development / Strategic planning
Financing – IPO – M&A
Here’s a partial list of companies in our Healthcare portfolio. They range from small University spin off companies to private or publicly traded companies. In some cases, InvHealth’s team is deeply involved in the development of the companies, while in others, it only performs due diligence for an investment decision during a financing round or in the secondary market.
Regardless of the size and maturity of the companies, there is one common denominator that drives the investment decision: The company must be providing tangible solutions (products and/or services) that address an unmet medical need with a clear regulatory pathway or that capitalize on a well-defined market trends (e.g. virtual monitoring of clinical trials, AI & diagnosis, plant-based proteins, genomics, etc.)
Innodem is a spin off company from McGill University that works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement
Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer’s, Parkinson’s or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.
Innovon Pharmaceuticals is a drug discovery company mainly focused on small molecules and peptides. Its business model consists in out-licensing drug candidates to pharmaceutical companies in
exchange for considerations including equity ownership in licensees, royalties on sales or on proceeds from other types of commercial transactions.
Innovon has a royalty interest for compounds licensed to Liminal Biosciences Inc.
Ortho RTI is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports
Its RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. ORTHO-R, our lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.
A multi- site US ORTHO-R Rotator Cuff Tear Repair Pilot Phase I/II clinical trial is being planned and organized for which an FDA IND submission was filed on April 4 2021. Considering the significant potential of our technology platform, Ortho RTI continues to assess new therapeutic target uses outside of the soft tissue repair field.
Further information about Ortho RTI is available on the Company’s website at www.orthorti.com
Ingenew’s primary focus is on oncology and inflammatory processes that lead to or are associated with cancer and its therapies.
Ingenew pursues pharmaceutical research designed to address well-defined unmet medical needs leading to tangible and affordable medical solutions. It has a balanced mix of proprietary products and platform technologies.
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases,
Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.
For more information, visit www.valeopharma.com
Burcon is a global technology leader in the development of plant-based proteins. With over 300 issued patents and more than 225 additional patent applications, that have been developed over a span of
more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives. Merit Foods has built a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon’s novel pea and canola protein ingredients.
For more information visit www.burcon.ca
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
For more information, visit veeva.com
Founded in 2012, Fulgent is developing flexible and affordable genetic testing that improves the everyday lives of those around us. Fulgent strives to create the most effective and wide ranging tests on the market.